The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives.
Stallmach, Andreas, Quickert, Stefanie, Puta, Christian et al. · Frontiers in immunology · 2024 · DOI
Quick Summary
This review examines whether changes in gut bacteria might play a role in ME/CFS, particularly in cases that develop after infections like COVID-19. The authors found that many ME/CFS patients do show differences in their gut bacteria compared to healthy people, and these changes might trigger immune and inflammatory problems. However, the review concludes that current research hasn't proven that gut bacteria changes actually cause ME/CFS—only that they often occur together.
Why It Matters
Understanding whether gut microbiota changes contribute to ME/CFS could identify new therapeutic targets for this debilitating condition lacking approved treatments. If dysbiosis is causally implicated, microbiota-modulating interventions (prebiotics, probiotics, dietary modifications) could potentially become evidence-based treatment options, offering hope to patients currently managing symptoms without specific medical therapies.
Observed Findings
Alterations in gastrointestinal microbiota composition are documented in ME/CFS patient cohorts
Microbial changes are associated with immunological and inflammatory pathway abnormalities in ME/CFS
Proposed mechanisms include intestinal barrier dysfunction, microbial translocation, and increased oxidative stress
Dysbiosis frequently co-occurs with ME/CFS symptoms, but causality remains unestablished
Most studies combine heterogeneous clinical presentations (IBS, fatigue, post-infection syndromes) in poorly characterized populations
Inferred Conclusions
Dysbiosis may represent a modifiable factor in ME/CFS pathophysiology worthy of therapeutic investigation
Microbiota-modulating strategies warrant clinical trial testing as potential treatments for ME/CFS and other PAIS
Robustly designed longitudinal studies with well-characterized, homogeneous patient populations are needed to establish causality
Drawing on mechanisms from other gastrointestinal diseases, microbiota modulation offers a rational therapeutic avenue despite current uncertainty about causation
Remaining Questions
Does dysbiosis cause ME/CFS, or is it a consequence of the disease and its associated lifestyle changes?
What This Study Does Not Prove
This review does not establish that gut microbiota changes cause ME/CFS—only that associations exist in some patient populations. The authors specifically highlight that current evidence cannot distinguish between dysbiosis as a primary driver versus a consequence of ME/CFS pathology or illness-related behavioral changes. The heterogeneous study populations and poorly defined patient cohorts limit any definitive conclusions about causality.